January 20,2010 - LONDON (Reuters) - A "silent pandemic" of chronic disease is creeping up on poor countries and will force pharmaceutical firms to take a more tiered approach to pricing some of their most lucrative medicines.
Drugs for diseases which were previously dominant only in the rich, well-fed world, such as diabetes, heart disease and cancer, are increasingly in demand in poorer nations in Asia and Africa, whose populations are now living longer.
But the price of many of these medicines and their unsuitability for emerging markets are high barriers to access.
Read more »


